Key Highlights

  • Shares are trading up 9.74% at $166.36, after touching a new 52-week high.
  • Third-quarter adjusted EPS of $1.37 beat the $1.30 consensus.
  • Full-year adjusted EPS guidance was raised to $5.40 to $5.45.

Revvity (NYSE:RVTY) shares are trading up 9.74% at $166.36 today after a third-quarter beat and a raised 2026 outlook, with the stock hitting a new 52-week high near $171.74 on above-average volume. The rally is well ahead of a flat healthcare sector ETF and a mixed broader market, and it follows two down sessions.

Revvity is a Waltham, Massachusetts-based health science and diagnostics company formerly known as PerkinElmer, rebranded in 2023 after divesting its applied, food and enterprise services businesses. It reports two segments, Life Sciences and Diagnostics, and generated about $2.9 billion in Revenue in 2025 with a recurring-revenue model that the company puts at more than 80% of sales.

Beat on Revenue and Earnings With Broadening AI-Related Demand

Adjusted EPS of $1.37 topped the $1.30 consensus, and revenue of about $729 million beat estimates of about $695 million. Pro forma organic growth was 7%, above the mid-single-digit expectation, with pro forma adjusted Operating Margin of 29.4% and EPS up 21% year over year.

Life Sciences grew 9%, with reagents up high single digits, instruments up strong mid-single digits and Signals software up high teens, while Diagnostics grew 5%. Management said pharma and biotech Demand is recovering and AI-related demand is spreading beyond high-content screening into high-throughput screening, detection, reagents and later imaging and in vivo. Bulk screening orders added about 100 basis points to reagent growth.

Diagnostics Margin Expands and Guidance Moves Higher

Diagnostics adjusted operating margin was 29.9%, or over 30% and up more than 600 basis points excluding the China immunodiagnostics Business to be divested. Immunodiagnostics grew high single digits, with U.S. growth above 20%. Free Cash Flow was $152 million, a 99% conversion, and net Leverage was 2.3x.

Full-year pro forma organic growth is now expected at about 5%, revenue at about $2.86 billion, adjusted operating margin at 28.8% and adjusted EPS at $5.40 to $5.45, about 12% growth. Fourth-quarter guidance calls for about 5% organic growth, revenue of about $755 million and an operating margin slightly above 32%.

Thermo Fisher Also Rises as Peers Report Demand Gains

The group is moving together, with Thermo Fisher Scientific (NYSE:TMO) also trading higher after its own beat. Revvity's average analyst price target remains below the current price.

November 13 Investor Day Is the Next Catalyst

Management expects 40%-plus incremental margins to be sustainable and plans to give more detail at its Investor Day on November 13. After a 10% gain to a fresh high, investors will look for long-term targets that justify the move.